During cardiac catheterizations in 20 cases with congenital heart disease, intracardiac shunts were measured by two methods, dye dilution method and the Fick method, and the results were compared. Arterial dilution curves were used for the estimation of both the right-to-left and left-to-right shunts-Venous dilution curves were used for measurement of left-to-right shunts. In cases with a left-to-right shunt, the amount of the shunt was expressed as per cent of total pulmonary blood flow and, in cases with a right-to-left shunt, as per cent of total systemic blood flow. The following results were obtained. 1. In 8 cases with a right-to-left shunt, the amount of the shunt was 35.6 +/-18.1% by the Fick method and 34.0 +/-19.2% by arterial dilution curves. The difference was not statistically significant(p> 0.l). In 15 cases with a left-to-right shunt, the amount of shunt was 41.3 +/-26.6% by the arterial dilution curve and 36.6 +/-14.O% by the Fick method. The difference was not statistically significant(p> 0.1). Also venous dilution curve was performed in 8 cases of left-to-right shunt and the amount of the shunt was 33.0 +/-21.0%, as compared to 35.5 +/-17.3% by the Fick methods. The difference was not statistically significant (p> 0.1). 2. Arterial dilution curves could be used to localize right-to-left shunts and venous dilution curves left-to-right shunts, whereas tile Fick method was helpful only for the localization of left-to-right shunts. 3. It was possible to detect small left-to-right (less than 10%) and right-to-left (less than 5%) shunts by dye dilution curves, which was not possible with the Fick method. 4. In detection of small intracardiac shunts as well as in shunt localization, the dye dilution method was more accurate than the Fick method. The difference of the amount of the shunt estimated by the two methods was not statistically significant.
Adolescent ; Adult ; Cardiac Output ; Child ; Child, Preschool ; Dye Dilution Technique ; Female ; Heart Defects, Congenital/*physiopathology ; *Heart Function Tests ; Human ; Male

Pure red cell aplasia (PRCA) in adults is usually idiopathic, although some underlying conditions can cause PRCA. Immunosuppressive therapy (IST) is used to treat PRCA, but IST has side effects and may fail. The anti-CD52 monoclonal antibody alemtuzumab (ALM) was recently used to successfully treat therapy-resistant PRCA. We herein report successful treatment of secondary PRCA after erythropoietin therapy using ALM and cyclosporin A (CsA) in one patient. The total dose of ALM was 60 mg over 3 days (10, 20, and 30 mg, respectively) plus CsA for at least 6 months. The patient achieved a complete response 18 months after ALM-CsA treatment and his treatment could be changed to a different erythropoietin-stimulating agent.
Adult ; Antibodies, Monoclonal, Humanized ; Cyclosporine ; Erythropoietin ; Humans ; Red-Cell Aplasia, Pure